Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328380 · ClinicalTrials.gov registry record · Phase 3
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
NCT00328380 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 660 participants.
The verdict
NCT00328380, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD) from all causes.
Interventions
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00328380
The ClinicalTrials.gov registry entry for NCT00328380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifaximin is the first listed.
NCT00328380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00328380 about?
NCT00328380 is a clinical study titled "Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.". The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD) from all causes.
What is the current status of trial NCT00328380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2005-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00328380?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT00328380?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.